We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amedisys (AMED - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amedisys is one of 1091 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amedisys is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AMED's full-year earnings has moved 5.6% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AMED has returned about 11.5% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.5% on a year-to-date basis. This shows that Amedisys is outperforming its peers so far this year.
Another stock in the Medical sector, Cybin Inc. (CYBN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 80.5%.
Over the past three months, Cybin Inc.'s consensus EPS estimate for the current year has increased 8.3%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Amedisys is a member of the Medical - Outpatient and Home Healthcare industry, which includes 17 individual companies and currently sits at #52 in the Zacks Industry Rank. On average, this group has lost an average of 10.3% so far this year, meaning that AMED is performing better in terms of year-to-date returns.
On the other hand, Cybin Inc. belongs to the Medical - Biomedical and Genetics industry. This 529-stock industry is currently ranked #82. The industry has moved -17.5% year to date.
Amedisys and Cybin Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amedisys (AMED - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amedisys is one of 1091 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amedisys is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AMED's full-year earnings has moved 5.6% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AMED has returned about 11.5% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.5% on a year-to-date basis. This shows that Amedisys is outperforming its peers so far this year.
Another stock in the Medical sector, Cybin Inc. (CYBN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 80.5%.
Over the past three months, Cybin Inc.'s consensus EPS estimate for the current year has increased 8.3%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Amedisys is a member of the Medical - Outpatient and Home Healthcare industry, which includes 17 individual companies and currently sits at #52 in the Zacks Industry Rank. On average, this group has lost an average of 10.3% so far this year, meaning that AMED is performing better in terms of year-to-date returns.
On the other hand, Cybin Inc. belongs to the Medical - Biomedical and Genetics industry. This 529-stock industry is currently ranked #82. The industry has moved -17.5% year to date.
Amedisys and Cybin Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.